JPMorgan Chase & Co. Raises TransMedics Group (NASDAQ:TMDX) Price Target to $127.00

TransMedics Group (NASDAQ:TMDX) had its price target lifted by JPMorgan Chase & Co. from $105.00 to $127.00 in a research report sent to investors on Wednesday, Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts also recently issued reports on the stock. Morgan Stanley boosted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an equal weight rating in a research note on Wednesday, February 28th. Oppenheimer upped their price target on TransMedics Group from $105.00 to $125.00 and gave the company an outperform rating in a research report on Wednesday. Finally, Piper Sandler restated an overweight rating and set a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research report on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $119.00.

TransMedics Group Trading Up 2.9 %

Shares of TMDX opened at $127.99 on Wednesday. The business’s 50-day moving average price is $85.54 and its 200 day moving average price is $76.85. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The stock has a market capitalization of $4.19 billion, a P/E ratio of -376.44 and a beta of 1.87. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $129.66.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. The business had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The firm’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.08) earnings per share. Analysts expect that TransMedics Group will post -0.14 earnings per share for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 63,260 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total value of $6,866,240.40. Following the transaction, the insider now directly owns 9,792 shares of the company’s stock, valued at approximately $1,062,823.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other TransMedics Group news, Director James R. Tobin sold 15,040 shares of TransMedics Group stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the sale, the director now directly owns 205,171 shares in the company, valued at $21,836,349.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 63,260 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the transaction, the insider now owns 9,792 shares in the company, valued at approximately $1,062,823.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 236,378 shares of company stock valued at $23,633,449. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently modified their holdings of TMDX. Venturi Wealth Management LLC acquired a new position in TransMedics Group during the first quarter worth $30,000. Fidelis Capital Partners LLC bought a new position in shares of TransMedics Group in the 1st quarter valued at approximately $35,000. Cutler Group LLC CA raised its stake in shares of TransMedics Group by 600.0% in the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after acquiring an additional 600 shares in the last quarter. RiverPark Advisors LLC acquired a new stake in TransMedics Group in the 3rd quarter worth approximately $60,000. Finally, First Horizon Advisors Inc. boosted its position in TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.